Herbalife on Track for Highest Close Since August 2023 — Data Talk

Check out the companies making headlines yesterday:

Herbalife : Health and wellness products company Herbalife rose by 6.9% on Tuesday after Maxim Group initiated coverage on the company with a "Buy" rating and a $20.00 price target. See our full article here.

Vertex Pharmaceuticals : Biotech company Vertex Pharmaceuticals rose by 3.8% on Tuesday after Wolfe Research upgraded the stock from "Peer Perform" to "Outperform" and issued a $548 price target. See our full article here.

Micron : Memory chips maker Micron (NYSE:MU) rose by 8.6% on Tuesday after a broader market rally drove investor optimism in artificial intelligence and big tech stocks. See our full article here.

Amkor : Semiconductor packaging and testing company Amkor Technology rose by 5.2% on Tuesday after investment firm Needham & Company significantly raised its price target on the stock, pointing to surging demand for artificial intelligence chips. See our full article here.

Palantir Technologies : Data analytics company Palantir Technologies rose by 2.9% on Tuesday after a broader market rally drove investor optimism in artificial intelligence and big tech stocks. See our full article here.

What Happened?

Shares of health and wellness products company Herbalife jumped 6.9% in the afternoon session after Maxim Group initiated coverage on the company with a "Buy" rating and a $20.00 price target. 

The price target suggested a significant potential upside from the stock's previous closing price of $12.91. This new analysis from Maxim Group analyst Anthony Vendetti appeared to give investors a fresh reason for optimism about the nutrition company's prospects. The initiation of coverage with a positive outlook often draws new attention to a stock, which can lead to increased buying activity.

What Is The Market Telling Us

Herbalife’s shares are extremely volatile and have had 30 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 26 days ago when the stock gained 3.4% on the news that an analyst upgraded the company's stock to 'Buy' following strong third-quarter results. 

Argus raised its rating and set a price target of $15 for Herbalife, citing expected revenue growth from new products. This positive view was supported by the company's recent performance. In its third-quarter 2025 earnings report, Herbalife posted revenue of $1.3 billion, which surpassed the anticipated $1.26 billion. The company also achieved an earnings per share of $0.50, beating the forecast of $0.46. The broader sentiment from analysts appeared positive, with a consensus 'Buy' rating noted across the board.

Herbalife is up 7.8% since the beginning of the year, and at $13.82 per share, it is trading close to its 52-week high of $14.90 from December 2025. Investors who bought $1,000 worth of Herbalife’s shares 5 years ago would now be looking at an investment worth $256.88.

Looking back on personal care stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Edgewell Personal Care and its peers.

While personal care products products may seem more discretionary than food, consumers tend to maintain or even boost their spending on the category during tough times. This phenomenon is known as "the lipstick effect" by economists, which states that consumers still want some semblance of affordable luxuries like beauty and wellness when the economy is sputtering. Consumer tastes are constantly changing, and personal care companies are currently responding to the public’s increased desire for ethically produced goods by featuring natural ingredients in their products.

The 12 personal care stocks we track reported a satisfactory Q3. As a group, revenues were in line with analysts’ consensus estimates while next quarter’s revenue guidance was 1.2% above.

Thankfully, share prices of the companies have been resilient as they are up 9.1% on average since the latest earnings results.

Weakest Q3: Edgewell Personal Care

Boasting brands such as Banana Boat, Schick, and Skintimate, Edgewell Personal Care sells personal care products in the skin and sun care, shave, and feminine care categories.

Edgewell Personal Care reported revenues of $537.2 million, up 3.8% year on year. This print exceeded analysts’ expectations by 0.6%. Despite the top-line beat, it was still a disappointing quarter for the company with a significant miss of analysts’ organic revenue and adjusted operating income estimates.

"Fiscal 2025 was a year of challenge and transformation. While both external and internal pressures impacted our results, we exited the year with encouraging momentum—marked by improving sales and market share trends and a revitalized brand portfolio," said Rod Little, Edgewell's President and Chief Executive Officer.

Unsurprisingly, the stock is down 4% since reporting and currently trades at $18.15.

Read our full report on Edgewell Personal Care here, it’s free for active Edge members.

Best Q3: Nature's Sunshine

Started on a kitchen table in Utah, Nature’s Sunshine manufactures and sells nutritional and personal care products.

Nature's Sunshine reported revenues of $128.3 million, up 12% year on year, outperforming analysts’ expectations by 6.7%. The business had a stunning quarter with a beat of analysts’ EPS and EBITDA estimates.

Nature's Sunshine delivered the biggest analyst estimates beat among its peers. The market seems happy with the results as the stock is up 60.4% since reporting. It currently trades at $21.98.

e.l.f. Beauty

Short for "eyes, lips, face", e.l.f. Beauty is a developer of high-quality beauty products at accessible price points.

e.l.f. Beauty reported revenues of $343.9 million, up 14.2% year on year, falling short of analysts’ expectations by 6.4%. It was a slower quarter as it posted full-year revenue guidance missing analysts’ expectations significantly and full-year EBITDA guidance missing analysts’ expectations significantly.

e.l.f. Beauty delivered the fastest revenue growth but had the weakest full-year guidance update in the group. As expected, the stock is down 34.3% since the results and currently trades at $78.98.

Read our full analysis of e.l.f. Beauty’s results here.

USANA

Going to market with a direct selling model rather than through traditional retailers, USANA Health Sciences manufactures and sells nutritional, personal care, and skincare products.

USANA reported revenues of $213.7 million, up 6.7% year on year. This print was in line with analysts’ expectations. More broadly, it was a satisfactory quarter as it also produced a solid beat of analysts’ EBITDA estimates but a miss of analysts’ gross margin estimates.

The stock is down 2.1% since reporting and currently trades at $20.48.

Read our full, actionable report on USANA here, it’s free for active Edge members.

Herbalife

With the first products sold out of the trunk of the founder’s car, Herbalife today offers a portfolio of shakes, supplements, personal care products, and weight management programs to help customers reach their nutritional and fitness goals.

Herbalife reported revenues of $1.27 billion, up 2.7% year on year. This result beat analysts’ expectations by 0.5%. Aside from that, it was a mixed quarter as it also recorded an impressive beat of analysts’ EBITDA estimates but a significant miss of analysts’ gross margin estimates.

The stock is up 72.9% since reporting and currently trades at $14.25.

Read our full, actionable report on Herbalife here, it’s free for active Edge members.

What Happened?

Shares of health and wellness products company Herbalife jumped 3.4% in the morning session after an analyst upgraded the company's stock to 'Buy' following strong third-quarter results. 

Argus raised its rating and set a price target of $15 for Herbalife, citing expected revenue growth from new products. This positive view was supported by the company's recent performance. In its third-quarter 2025 earnings report, Herbalife posted revenue of $1.3 billion, which surpassed the anticipated $1.26 billion. 

The company also achieved an earnings per share of $0.50, beating the forecast of $0.46. The broader sentiment from analysts appeared positive, with a consensus 'Buy' rating noted across the board.

After the initial pop the shares cooled down to $14.02, up 3.9% from previous close.

Is now the time to buy Herbalife? Access our full analysis report here.

What Is The Market Telling Us

Herbalife’s shares are extremely volatile and have had 30 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 3 days ago when the stock dropped 2.8% on the news that investor concerns grew over the company's financial health, highlighted by shrinking sales and sluggish growth forecasts. 

Analysis pointed to shrinking unit sales over the previous two years and a projected sales growth of only 2.9% for the next twelve months, suggesting weak demand. Furthermore, the company's earnings per share had decreased more than its revenue, partly because it diluted shareholders. 

Adding to the negative sentiment were potential business risks, including regulatory compliance and uncertain consumer demand. An analyst from Mizuho also previously set a price target of $11.00, which implied an expectation for the stock to fall.

Herbalife is up 110% since the beginning of the year, and at $14.02 per share, has set a new 52-week high. Investors who bought $1,000 worth of Herbalife’s shares 5 years ago would now be looking at an investment worth $287.12.

What a fantastic six months it’s been for Herbalife. Shares of the company have skyrocketed 48.3%, hitting $11.76. This run-up might have investors contemplating their next move.

Is there a buying opportunity in Herbalife, or does it present a risk to your portfolio? Get the full stock story straight from our expert analysts, it’s free for active Edge members.

Why Is Herbalife Not Exciting?

We’re glad investors have benefited from the price increase, but we don't have much confidence in Herbalife. Here are three reasons we avoid HLF and a stock we'd rather own.

1. Demand Slipping as Sales Volumes Decline

Revenue growth can be broken down into changes in price and volume (the number of units sold). While both are important, volume is the lifeblood of a successful staples business as there’s a ceiling to what consumers will pay for everyday goods; they can always trade down to non-branded products if the branded versions are too expensive.

Herbalife’s average quarterly sales volumes have shrunk by 3.5% over the last two years. This decrease isn’t ideal because the quantity demanded for consumer staples products is typically stable.

2. Projected Revenue Growth Is Slim

Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite.

Over the next 12 months, sell-side analysts expect Herbalife’s revenue to rise by 2.9%. While this projection suggests its newer products will spur better top-line performance, it is still below the sector average.

3. EPS Trending Down

We track the change in earnings per share (EPS) because it highlights whether a company’s growth is profitable.

Sadly for Herbalife, its EPS declined by 15.9% annually over the last three years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand.

Final Judgment

Herbalife isn’t a terrible business, but it isn’t one of our picks. Following the recent rally, the stock trades at 4.6× forward P/E (or $11.76 per share). While this valuation is reasonable, we don’t really see a big opportunity at the moment. We're fairly confident there are better stocks to buy right now. Let us point you toward the most dominant software business in the world.